Andrew J. Wagner

Also affiliated with Dana-Farber Cancer Institute

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Data from Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial

(2023)10.1158/1078-0432.c.6530537

Top 100%

0DataRank

Top 100%0 citations

Andrew J. Wagner, Akira Kawai, Kazuo Tamura, Ashwin Shahir, Brian A. Van Tine +5 more

Papers

Driven by 13 papers — median percentile 0. Top paper: “Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial”.

Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4592

N/A

2.3DataRank · unranked

46 citations

Andrew J. Wagner, Akira Kawai, Kazuo Tamura, Ashwin Shahir, Brian A. Van Tine +5 more

Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors

The Oncologist(2020)10.1002/onco.13629

N/A

1.9DataRank · unranked

61 citations

Hans Gelderblom, Michiel A. J. van de Sande, Silvia Stacchiotti, John H. Healey, William D. Tap +10 more

Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial

The Lancet(2024)10.1016/s0140-6736(24)01812-9

N/A

1.4DataRank · unranked

84 citations

Karla V. Ballman, Angela Hong, Scott M. Schuetze, Andrew J. Wagner, Varun Monga +23 more

Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-2250

N/A

0.979DataRank · unranked

35 citations

Michael J. Nathenson, Emanuele Mazzola, Jia‐Ren Lin, Joanna Bagińska, Allison Nau +11 more

Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2007

N/A

0.965DataRank · unranked

32 citations

Arun S. Singh, Stephen P. Anthony, Mike Sterba, Chao Zhang, John H. Healey +19 more

Ultra‐rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities

Cancer(2021)10.1002/cncr.33618

N/A

0DataRank · unranked

229 citations

Anna Maria Frezza, Jean‐Yves Blay, Elizabeth H. Baldini, Sylvie Bonvalot, Judith V.M.G. Bovée +52 more

Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network

Annals of Oncology(2020)10.1016/j.annonc.2020.08.2232

N/A

0DataRank · unranked

146 citations

Cristina R. Antonescu, Bodil Bjerkehagen, Judith V.M.G. Bovée, Kjetil Boye, Matías Chacón +43 more

Exposure–response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor

CPT Pharmacometrics & Systems Pharmacology(2021)10.1002/psp4.12712

N/A

0DataRank · unranked

10 citations

Hamim Zahir, Jonathan French, Daniel Polhamus, Xiaoning Wang, Michiel A. J. van de Sande +8 more

Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma

Nature Communications(2022)10.1038/s41467-022-30496-0

N/A

0DataRank · unranked

194 citations

Narasimhan P. Agaram, Sally E. Trabucco, Victoria Robinson, Richard Ferraro, Sherri Z. Millis +38 more

Distinct oncogenic signatures in malignant PEComa and leiomyosarcoma identified by integrative RNA-seq and H3K27ac ChIP-seq analysis.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.11552

N/A

0DataRank · unranked

2 citations

Ahmad-Abdel Azim, Elio Adib, Inga‐Marie Schaefer, Nikolas Kesten, Len Taing +8 more

Data from Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial

(2023)10.1158/1078-0432.c.6530537

Top 100%

0DataRank

Top 100%0 citations

Andrew J. Wagner, Akira Kawai, Kazuo Tamura, Ashwin Shahir, Brian A. Van Tine +5 more

Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors

The Journal of Clinical Pharmacology(2020)10.1002/jcph.1753

N/A

0DataRank · unranked

12 citations

Andrew J. Wagner, Jia Kang, William Knebel, Hamim Zahir, Michiel A. J. van de Sande +6 more

Long‐term outcomes of pexidartinib in tenosynovial giant cell tumors

Cancer(2020)10.1002/cncr.33312

N/A

0DataRank · unranked

70 citations

Andrew J. Wagner, William D. Tap, Emanuela Palmerini, Zev A. Wainberg, Jayesh Desai +11 more

Andrew J. Wagner

Indexed papers

Top data-sharing exemplar

Papers